nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisatracurium Besylate—CHRND—pericardium—lung cancer	0.077	0.652	CbGeAlD
Cisatracurium Besylate—CHRND—Highly sodium permeable acetylcholine nicotinic receptors—CHRNB4—lung cancer	0.0229	0.0469	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Highly sodium permeable acetylcholine nicotinic receptors—CHRNA3—lung cancer	0.0174	0.0356	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Highly calcium permeable nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0159	0.0326	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—mammary gland—lung cancer	0.0152	0.129	CbGeAlD
Cisatracurium Besylate—CHRNA2—Highly calcium permeable nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0151	0.031	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Presynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0149	0.0305	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0148	0.0303	CbGpPWpGaD
Cisatracurium Besylate—CHRND—respiratory system—lung cancer	0.0147	0.124	CbGeAlD
Cisatracurium Besylate—CHRNA2—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0141	0.0288	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Presynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0138	0.0284	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0136	0.0278	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Acetylcholine Binding And Downstream Events—CHRNB4—lung cancer	0.0132	0.027	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0129	0.0264	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Presynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.0127	0.0259	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0126	0.0258	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Acetylcholine Binding And Downstream Events—CHRNA5—lung cancer	0.0122	0.0251	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.0121	0.0247	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Presynaptic nicotinic acetylcholine receptors—CHRNB4—lung cancer	0.012	0.0246	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.012	0.0246	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Presynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0118	0.0241	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Highly calcium permeable nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.0115	0.0235	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Presynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.0113	0.0231	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Acetylcholine Binding And Downstream Events—CHRNB4—lung cancer	0.0112	0.0229	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Presynaptic nicotinic acetylcholine receptors—CHRNA5—lung cancer	0.0112	0.0229	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Acetylcholine Binding And Downstream Events—CHRNB4—lung cancer	0.0106	0.0218	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Acetylcholine Binding And Downstream Events—CHRNA5—lung cancer	0.0104	0.0213	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.0103	0.0211	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Acetylcholine Binding And Downstream Events—CHRNA3—lung cancer	0.00997	0.0204	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Acetylcholine Binding And Downstream Events—CHRNA5—lung cancer	0.00988	0.0202	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Highly calcium permeable postsynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00976	0.02	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Presynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00959	0.0197	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Presynaptic nicotinic acetylcholine receptors—CHRNA3—lung cancer	0.00911	0.0187	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Acetylcholine Binding And Downstream Events—CHRNA3—lung cancer	0.00847	0.0174	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Acetylcholine Binding And Downstream Events—CHRNA3—lung cancer	0.00805	0.0165	CbGpPWpGaD
Cisatracurium Besylate—CHRND—lung—lung cancer	0.00779	0.0659	CbGeAlD
Cisatracurium Besylate—CHRNB1—lymph node—lung cancer	0.00343	0.0291	CbGeAlD
Cisatracurium Besylate—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIK3—lung cancer	0.00256	0.00524	CbGpPWpGaD
Cisatracurium Besylate—Cardiovascular disorder—Etoposide—lung cancer	0.0025	0.00634	CcSEcCtD
Cisatracurium Besylate—Angioedema—Gefitinib—lung cancer	0.00247	0.00627	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Methotrexate—lung cancer	0.00247	0.00626	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Crizotinib—lung cancer	0.00238	0.00605	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Crizotinib—lung cancer	0.00236	0.00599	CcSEcCtD
Cisatracurium Besylate—Flushing—Teniposide—lung cancer	0.00235	0.00597	CcSEcCtD
Cisatracurium Besylate—Hypertension—Pemetrexed—lung cancer	0.00235	0.00596	CcSEcCtD
Cisatracurium Besylate—Wheezing—Cisplatin—lung cancer	0.00233	0.0059	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Pemetrexed—lung cancer	0.0023	0.00584	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Gefitinib—lung cancer	0.00229	0.0058	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Pemetrexed—lung cancer	0.00222	0.00564	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Pemetrexed—lung cancer	0.00218	0.00553	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIK3—lung cancer	0.00217	0.00446	CbGpPWpGaD
Cisatracurium Besylate—Dyspnoea—Crizotinib—lung cancer	0.00217	0.0055	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Gefitinib—lung cancer	0.00216	0.00549	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Pemetrexed—lung cancer	0.00216	0.00548	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Gefitinib—lung cancer	0.00214	0.00544	CcSEcCtD
Cisatracurium Besylate—Wheezing—Paclitaxel—lung cancer	0.00209	0.0053	CcSEcCtD
Cisatracurium Besylate—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—lung cancer	0.00208	0.00427	CbGpPWpGaD
Cisatracurium Besylate—Injury—Irinotecan—lung cancer	0.00208	0.00529	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Methotrexate—lung cancer	0.00207	0.00525	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GRIK3—lung cancer	0.00207	0.00423	CbGpPWpGaD
Cisatracurium Besylate—Hypotension—Gefitinib—lung cancer	0.00206	0.00523	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Vinorelbine—lung cancer	0.00205	0.0052	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Pemetrexed—lung cancer	0.00198	0.00503	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Irinotecan—lung cancer	0.00198	0.00502	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Vinorelbine—lung cancer	0.00197	0.00501	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Gefitinib—lung cancer	0.00197	0.00499	CcSEcCtD
Cisatracurium Besylate—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—lung cancer	0.00194	0.00397	CbGpPWpGaD
Cisatracurium Besylate—Anaphylactoid reaction—Gemcitabine—lung cancer	0.00193	0.00489	CcSEcCtD
Cisatracurium Besylate—CHRND—Transmission across Chemical Synapses—GRIK3—lung cancer	0.00192	0.00394	CbGpPWpGaD
Cisatracurium Besylate—Hypertension—Teniposide—lung cancer	0.0019	0.00483	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Erlotinib—lung cancer	0.00183	0.00463	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Irinotecan—lung cancer	0.00182	0.00462	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Cisplatin—lung cancer	0.0018	0.00456	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—lung cancer	0.00177	0.00363	CbGpPWpGaD
Cisatracurium Besylate—Urticaria—Pemetrexed—lung cancer	0.00176	0.00448	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Teniposide—lung cancer	0.00176	0.00446	CcSEcCtD
Cisatracurium Besylate—Urticaria—Gefitinib—lung cancer	0.00175	0.00445	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Topotecan—lung cancer	0.0017	0.00432	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—ERBB3—lung cancer	0.0017	0.00348	CbGpPWpGaD
Cisatracurium Besylate—Injury—Paclitaxel—lung cancer	0.0017	0.00431	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Topotecan—lung cancer	0.0017	0.0043	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Topotecan—lung cancer	0.00169	0.00429	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNB4—lung cancer	0.00168	0.00345	CbGpPWpGaD
Cisatracurium Besylate—Hypotension—Teniposide—lung cancer	0.00168	0.00427	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Erlotinib—lung cancer	0.00167	0.00425	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—lung cancer	0.00165	0.00338	CbGpPWpGaD
Cisatracurium Besylate—Anaphylactoid reaction—Etoposide—lung cancer	0.00165	0.00418	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Pemetrexed—lung cancer	0.00164	0.00415	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Transmission across Chemical Synapses—GRIK3—lung cancer	0.00163	0.00335	CbGpPWpGaD
Cisatracurium Besylate—Hypersensitivity—Gefitinib—lung cancer	0.00163	0.00413	CcSEcCtD
Cisatracurium Besylate—Erythema—Erlotinib—lung cancer	0.00162	0.0041	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Teniposide—lung cancer	0.0016	0.00407	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Gemcitabine—lung cancer	0.00159	0.00402	CcSEcCtD
Cisatracurium Besylate—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—lung cancer	0.00158	0.00324	CbGpPWpGaD
Cisatracurium Besylate—Connective tissue disorder—Vinorelbine—lung cancer	0.00158	0.00401	CcSEcCtD
Cisatracurium Besylate—Pruritus—Pemetrexed—lung cancer	0.00157	0.00399	CcSEcCtD
Cisatracurium Besylate—CHRND—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.00157	0.00321	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA5—lung cancer	0.00157	0.00321	CbGpPWpGaD
Cisatracurium Besylate—Pruritus—Gefitinib—lung cancer	0.00156	0.00396	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Transmission across Chemical Synapses—GRIK3—lung cancer	0.00155	0.00318	CbGpPWpGaD
Cisatracurium Besylate—Rash—Crizotinib—lung cancer	0.00153	0.00389	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Crizotinib—lung cancer	0.00153	0.00389	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Etoposide—lung cancer	0.00151	0.00384	CcSEcCtD
Cisatracurium Besylate—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG11—lung cancer	0.00149	0.00306	CbGpPWpGaD
Cisatracurium Besylate—Angioedema—Topotecan—lung cancer	0.00149	0.00379	CcSEcCtD
Cisatracurium Besylate—Flushing—Vinorelbine—lung cancer	0.00149	0.00378	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Paclitaxel—lung cancer	0.00148	0.00377	CcSEcCtD
Cisatracurium Besylate—CHRND—Neuronal System—GRIK3—lung cancer	0.00147	0.00302	CbGpPWpGaD
Cisatracurium Besylate—Convulsion—Vinblastine—lung cancer	0.00146	0.0037	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Vinorelbine—lung cancer	0.00146	0.0037	CcSEcCtD
Cisatracurium Besylate—CHRND—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.00146	0.00299	CbGpPWpGaD
Cisatracurium Besylate—Hypertension—Vinblastine—lung cancer	0.00145	0.00369	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Vinorelbine—lung cancer	0.00145	0.00368	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Vinorelbine—lung cancer	0.00145	0.00367	CcSEcCtD
Cisatracurium Besylate—Urticaria—Teniposide—lung cancer	0.00143	0.00363	CcSEcCtD
Cisatracurium Besylate—Rash—Pemetrexed—lung cancer	0.0014	0.00355	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Pemetrexed—lung cancer	0.0014	0.00355	CcSEcCtD
Cisatracurium Besylate—Erythema—Vinorelbine—lung cancer	0.0014	0.00355	CcSEcCtD
Cisatracurium Besylate—Rash—Gefitinib—lung cancer	0.00139	0.00353	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Gefitinib—lung cancer	0.00139	0.00353	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Topotecan—lung cancer	0.00138	0.00351	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Paclitaxel—lung cancer	0.00138	0.00349	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—lung cancer	0.00137	0.00347	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Etoposide—lung cancer	0.00135	0.00344	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Irinotecan—lung cancer	0.00135	0.00342	CcSEcCtD
Cisatracurium Besylate—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY1—lung cancer	0.00134	0.00275	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—lung cancer	0.00134	0.00275	CbGpPWpGaD
Cisatracurium Besylate—Anaphylactic shock—Topotecan—lung cancer	0.00133	0.00338	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.00133	0.00273	CbGpPWpGaD
Cisatracurium Besylate—Hypersensitivity—Teniposide—lung cancer	0.00133	0.00336	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Topotecan—lung cancer	0.00131	0.00332	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Irinotecan—lung cancer	0.0013	0.0033	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Topotecan—lung cancer	0.0013	0.00329	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Doxorubicin—lung cancer	0.00129	0.00329	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Erlotinib—lung cancer	0.00129	0.00328	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Erlotinib—lung cancer	0.00128	0.00325	CcSEcCtD
Cisatracurium Besylate—Angioedema—Vinorelbine—lung cancer	0.00128	0.00324	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CHRNA3—lung cancer	0.00128	0.00262	CbGpPWpGaD
Cisatracurium Besylate—Pruritus—Teniposide—lung cancer	0.00127	0.00323	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG11—lung cancer	0.00127	0.0026	CbGpPWpGaD
Cisatracurium Besylate—Connective tissue disorder—Gemcitabine—lung cancer	0.00127	0.00322	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Transmission across Chemical Synapses—CHRNB4—lung cancer	0.00127	0.00259	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Neuronal System—GRIK3—lung cancer	0.00125	0.00257	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.00124	0.00254	CbGpPWpGaD
Cisatracurium Besylate—Flushing—Irinotecan—lung cancer	0.00123	0.00312	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Cisplatin—lung cancer	0.00122	0.00311	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—MAP2K1—lung cancer	0.00121	0.00249	CbGpPWpGaD
Cisatracurium Besylate—Hypertension—Vinorelbine—lung cancer	0.00121	0.00306	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG11—lung cancer	0.00121	0.00247	CbGpPWpGaD
Cisatracurium Besylate—Angiopathy—Irinotecan—lung cancer	0.0012	0.00305	CcSEcCtD
Cisatracurium Besylate—CHRND—Neuronal System—CHRNB4—lung cancer	0.0012	0.00246	CbGpPWpGaD
Cisatracurium Besylate—Immune system disorder—Irinotecan—lung cancer	0.0012	0.00304	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Irinotecan—lung cancer	0.00119	0.00303	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neuronal System—GRIK3—lung cancer	0.00119	0.00244	CbGpPWpGaD
Cisatracurium Besylate—Dyspnoea—Topotecan—lung cancer	0.00119	0.00302	CcSEcCtD
Cisatracurium Besylate—CHRND—Transmission across Chemical Synapses—CHRNA3—lung cancer	0.00119	0.00243	CbGpPWpGaD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.00118	0.003	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Cisplatin—lung cancer	0.00118	0.003	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Transmission across Chemical Synapses—CHRNA5—lung cancer	0.00118	0.00241	CbGpPWpGaD
Cisatracurium Besylate—Dyspnoea—Erlotinib—lung cancer	0.00118	0.00299	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Gemcitabine—lung cancer	0.00117	0.00297	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Gemcitabine—lung cancer	0.00117	0.00296	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Gemcitabine—lung cancer	0.00116	0.00295	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY1—lung cancer	0.00114	0.00234	CbGpPWpGaD
Cisatracurium Besylate—Anaphylactic shock—Vinorelbine—lung cancer	0.00114	0.0029	CcSEcCtD
Cisatracurium Besylate—Rash—Teniposide—lung cancer	0.00113	0.00288	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Teniposide—lung cancer	0.00113	0.00288	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Docetaxel—lung cancer	0.00113	0.00286	CcSEcCtD
Cisatracurium Besylate—Erythema—Gemcitabine—lung cancer	0.00112	0.00285	CcSEcCtD
Cisatracurium Besylate—CHRND—Transmission across Chemical Synapses—GNG11—lung cancer	0.00112	0.0023	CbGpPWpGaD
Cisatracurium Besylate—Nervous system disorder—Vinorelbine—lung cancer	0.00112	0.00284	CcSEcCtD
Cisatracurium Besylate—CHRND—Neuronal System—CHRNA5—lung cancer	0.00112	0.00229	CbGpPWpGaD
Cisatracurium Besylate—Flushing—Cisplatin—lung cancer	0.00112	0.00283	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Vinorelbine—lung cancer	0.00111	0.00283	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Vinorelbine—lung cancer	0.00111	0.00281	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Paclitaxel—lung cancer	0.0011	0.00279	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Cisplatin—lung cancer	0.00109	0.00276	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ADCY1—lung cancer	0.00108	0.00222	CbGpPWpGaD
Cisatracurium Besylate—Mediastinal disorder—Cisplatin—lung cancer	0.00108	0.00275	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—RAF1—lung cancer	0.00108	0.00221	CbGpPWpGaD
Cisatracurium Besylate—Hypotension—Vinorelbine—lung cancer	0.00107	0.00271	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—ERBB2—lung cancer	0.00107	0.00218	CbGpPWpGaD
Cisatracurium Besylate—Connective tissue disorder—Paclitaxel—lung cancer	0.00106	0.00269	CcSEcCtD
Cisatracurium Besylate—Urticaria—Topotecan—lung cancer	0.00106	0.00269	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—PIK3CB—lung cancer	0.00105	0.00216	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—MTOR—lung cancer	0.00105	0.00216	CbGpPWpGaD
Cisatracurium Besylate—Erythema—Cisplatin—lung cancer	0.00105	0.00266	CcSEcCtD
Cisatracurium Besylate—Flushing—Etoposide—lung cancer	0.00102	0.00259	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neuronal System—CHRNB4—lung cancer	0.00102	0.00209	CbGpPWpGaD
Cisatracurium Besylate—Dyspnoea—Vinorelbine—lung cancer	0.00102	0.00258	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Vinblastine—lung cancer	0.00101	0.00257	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Transmission across Chemical Synapses—CHRNA3—lung cancer	0.00101	0.00207	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Transmission across Chemical Synapses—ADCY1—lung cancer	0.00101	0.00207	CbGpPWpGaD
Cisatracurium Besylate—Flushing—Paclitaxel—lung cancer	0.001	0.00254	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Etoposide—lung cancer	0.000999	0.00254	CcSEcCtD
Cisatracurium Besylate—Hypertension—Irinotecan—lung cancer	0.000995	0.00253	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Etoposide—lung cancer	0.000995	0.00253	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Etoposide—lung cancer	0.000993	0.00252	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Methotrexate—lung cancer	0.000986	0.0025	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Topotecan—lung cancer	0.000983	0.00249	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Paclitaxel—lung cancer	0.00098	0.00249	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Paclitaxel—lung cancer	0.000976	0.00248	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Paclitaxel—lung cancer	0.000973	0.00247	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neuronal System—CHRNB4—lung cancer	0.00097	0.00199	CbGpPWpGaD
Cisatracurium Besylate—Hypertension—Gemcitabine—lung cancer	0.00097	0.00246	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Transmission across Chemical Synapses—CHRNA3—lung cancer	0.000959	0.00197	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Transmission across Chemical Synapses—GNG11—lung cancer	0.000955	0.00196	CbGpPWpGaD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.00095	0.00241	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neuronal System—CHRNA5—lung cancer	0.000949	0.00195	CbGpPWpGaD
Cisatracurium Besylate—Pruritus—Topotecan—lung cancer	0.000944	0.00239	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Irinotecan—lung cancer	0.000941	0.00239	CcSEcCtD
Cisatracurium Besylate—Erythema—Paclitaxel—lung cancer	0.00094	0.00239	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—JUN—lung cancer	0.000939	0.00193	CbGpPWpGaD
Cisatracurium Besylate—Pruritus—Erlotinib—lung cancer	0.000934	0.00237	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Irinotecan—lung cancer	0.000923	0.00234	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Gemcitabine—lung cancer	0.000917	0.00233	CcSEcCtD
Cisatracurium Besylate—CHRND—Neuronal System—CHRNA3—lung cancer	0.00091	0.00187	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Transmission across Chemical Synapses—GNG11—lung cancer	0.000907	0.00186	CbGpPWpGaD
Cisatracurium Besylate—Convulsion—Cisplatin—lung cancer	0.000907	0.0023	CcSEcCtD
Cisatracurium Besylate—Urticaria—Vinorelbine—lung cancer	0.000906	0.0023	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neuronal System—CHRNA5—lung cancer	0.000902	0.00185	CbGpPWpGaD
Cisatracurium Besylate—Connective tissue disorder—Docetaxel—lung cancer	0.0009	0.00228	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Gemcitabine—lung cancer	0.000899	0.00228	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Gemcitabine—lung cancer	0.00089	0.00226	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000885	0.00225	CcSEcCtD
Cisatracurium Besylate—Hypotension—Irinotecan—lung cancer	0.000879	0.00223	CcSEcCtD
Cisatracurium Besylate—CHRND—Neuronal System—GNG11—lung cancer	0.00086	0.00176	CbGpPWpGaD
Cisatracurium Besylate—Angioedema—Paclitaxel—lung cancer	0.000859	0.00218	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Transmission across Chemical Synapses—ADCY1—lung cancer	0.000859	0.00176	CbGpPWpGaD
Cisatracurium Besylate—Hypotension—Gemcitabine—lung cancer	0.000856	0.00217	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Cisplatin—lung cancer	0.000854	0.00217	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Doxorubicin—lung cancer	0.000853	0.00217	CcSEcCtD
Cisatracurium Besylate—Flushing—Docetaxel—lung cancer	0.00085	0.00216	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—SRC—lung cancer	0.000843	0.00173	CbGpPWpGaD
Cisatracurium Besylate—Rash—Topotecan—lung cancer	0.000841	0.00213	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Vinorelbine—lung cancer	0.000841	0.00213	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Topotecan—lung cancer	0.00084	0.00213	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Irinotecan—lung cancer	0.000839	0.00213	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Cisplatin—lung cancer	0.000838	0.00213	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Cisplatin—lung cancer	0.000834	0.00212	CcSEcCtD
Cisatracurium Besylate—Rash—Erlotinib—lung cancer	0.000832	0.00211	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Erlotinib—lung cancer	0.000831	0.00211	CcSEcCtD
Cisatracurium Besylate—Convulsion—Etoposide—lung cancer	0.000831	0.00211	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Docetaxel—lung cancer	0.000831	0.00211	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Cisplatin—lung cancer	0.00083	0.00211	CcSEcCtD
Cisatracurium Besylate—Hypertension—Etoposide—lung cancer	0.000828	0.0021	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Docetaxel—lung cancer	0.000827	0.0021	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Docetaxel—lung cancer	0.000825	0.00209	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Gemcitabine—lung cancer	0.000817	0.00207	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Transmission across Chemical Synapses—ADCY1—lung cancer	0.000816	0.00167	CbGpPWpGaD
Cisatracurium Besylate—Convulsion—Paclitaxel—lung cancer	0.000815	0.00207	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—STAT3—lung cancer	0.000813	0.00167	CbGpPWpGaD
Cisatracurium Besylate—Hypertension—Paclitaxel—lung cancer	0.000812	0.00206	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000811	0.00206	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—NRAS—lung cancer	0.000811	0.00166	CbGpPWpGaD
Cisatracurium Besylate—Pruritus—Vinorelbine—lung cancer	0.000807	0.00205	CcSEcCtD
Cisatracurium Besylate—Hypotension—Cisplatin—lung cancer	0.000798	0.00203	CcSEcCtD
Cisatracurium Besylate—Erythema—Docetaxel—lung cancer	0.000797	0.00202	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000795	0.00202	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Doxorubicin—lung cancer	0.000785	0.00199	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Etoposide—lung cancer	0.000783	0.00199	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—MAPK3—lung cancer	0.000776	0.00159	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Neuronal System—CHRNA3—lung cancer	0.000774	0.00159	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Neuronal System—ADCY1—lung cancer	0.000774	0.00159	CbGpPWpGaD
Cisatracurium Besylate—Anaphylactic shock—Paclitaxel—lung cancer	0.000767	0.00195	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Etoposide—lung cancer	0.000764	0.00194	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Cisplatin—lung cancer	0.000762	0.00193	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Etoposide—lung cancer	0.00076	0.00193	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Paclitaxel—lung cancer	0.000753	0.00191	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Paclitaxel—lung cancer	0.000749	0.0019	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Paclitaxel—lung cancer	0.000745	0.00189	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neuronal System—CHRNA3—lung cancer	0.000735	0.00151	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Neuronal System—GNG11—lung cancer	0.000732	0.0015	CbGpPWpGaD
Cisatracurium Besylate—Hypotension—Etoposide—lung cancer	0.000731	0.00186	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Doxorubicin—lung cancer	0.000728	0.00185	CcSEcCtD
Cisatracurium Besylate—Rash—Vinorelbine—lung cancer	0.000719	0.00183	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Vinorelbine—lung cancer	0.000719	0.00182	CcSEcCtD
Cisatracurium Besylate—Hypotension—Paclitaxel—lung cancer	0.000717	0.00182	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Etoposide—lung cancer	0.000698	0.00177	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—KRAS—lung cancer	0.000698	0.00143	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Neuronal System—GNG11—lung cancer	0.000695	0.00142	CbGpPWpGaD
Cisatracurium Besylate—Hypersensitivity—Irinotecan—lung cancer	0.000693	0.00176	CcSEcCtD
Cisatracurium Besylate—Convulsion—Docetaxel—lung cancer	0.000691	0.00175	CcSEcCtD
Cisatracurium Besylate—Hypertension—Docetaxel—lung cancer	0.000688	0.00175	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Paclitaxel—lung cancer	0.000684	0.00174	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000674	0.00171	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neuronal System—ADCY1—lung cancer	0.000658	0.00135	CbGpPWpGaD
Cisatracurium Besylate—Anaphylactic shock—Docetaxel—lung cancer	0.00065	0.00165	CcSEcCtD
Cisatracurium Besylate—Pruritus—Gemcitabine—lung cancer	0.000648	0.00165	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—PIK3CA—lung cancer	0.000641	0.00131	CbGpPWpGaD
Cisatracurium Besylate—Nervous system disorder—Docetaxel—lung cancer	0.000638	0.00162	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Docetaxel—lung cancer	0.000635	0.00161	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Docetaxel—lung cancer	0.000632	0.0016	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Cisplatin—lung cancer	0.000629	0.0016	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neuronal System—ADCY1—lung cancer	0.000625	0.00128	CbGpPWpGaD
Cisatracurium Besylate—Urticaria—Etoposide—lung cancer	0.000622	0.00158	CcSEcCtD
Cisatracurium Besylate—Urticaria—Paclitaxel—lung cancer	0.00061	0.00155	CcSEcCtD
Cisatracurium Besylate—Hypotension—Docetaxel—lung cancer	0.000608	0.00154	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Methotrexate—lung cancer	0.000599	0.00152	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Methotrexate—lung cancer	0.000596	0.00151	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Methotrexate—lung cancer	0.000595	0.00151	CcSEcCtD
Cisatracurium Besylate—Rash—Irinotecan—lung cancer	0.000593	0.00151	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—HRAS—lung cancer	0.000593	0.00122	CbGpPWpGaD
Cisatracurium Besylate—Dermatitis—Irinotecan—lung cancer	0.000593	0.0015	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Doxorubicin—lung cancer	0.000582	0.00148	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Docetaxel—lung cancer	0.00058	0.00147	CcSEcCtD
Cisatracurium Besylate—Rash—Gemcitabine—lung cancer	0.000578	0.00147	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Gemcitabine—lung cancer	0.000577	0.00147	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Etoposide—lung cancer	0.000577	0.00146	CcSEcCtD
Cisatracurium Besylate—Erythema—Methotrexate—lung cancer	0.000574	0.00146	CcSEcCtD
Cisatracurium Besylate—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—lung cancer	0.000568	0.00116	CbGpPWpGaD
Cisatracurium Besylate—Hypersensitivity—Paclitaxel—lung cancer	0.000565	0.00143	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Doxorubicin—lung cancer	0.000561	0.00143	CcSEcCtD
Cisatracurium Besylate—Pruritus—Etoposide—lung cancer	0.000554	0.00141	CcSEcCtD
Cisatracurium Besylate—Pruritus—Paclitaxel—lung cancer	0.000543	0.00138	CcSEcCtD
Cisatracurium Besylate—Rash—Cisplatin—lung cancer	0.000539	0.00137	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Cisplatin—lung cancer	0.000538	0.00137	CcSEcCtD
Cisatracurium Besylate—Flushing—Doxorubicin—lung cancer	0.00053	0.00135	CcSEcCtD
Cisatracurium Besylate—CHRNA1—ErbB2/ErbB3 signaling events—AKT1—lung cancer	0.000524	0.00107	CbGpPWpGaD
Cisatracurium Besylate—Angiopathy—Doxorubicin—lung cancer	0.000518	0.00132	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Doxorubicin—lung cancer	0.000516	0.00131	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Doxorubicin—lung cancer	0.000515	0.00131	CcSEcCtD
Cisatracurium Besylate—Convulsion—Methotrexate—lung cancer	0.000498	0.00126	CcSEcCtD
Cisatracurium Besylate—Erythema—Doxorubicin—lung cancer	0.000497	0.00126	CcSEcCtD
Cisatracurium Besylate—Rash—Etoposide—lung cancer	0.000493	0.00125	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Etoposide—lung cancer	0.000493	0.00125	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000486	0.00123	CcSEcCtD
Cisatracurium Besylate—Rash—Paclitaxel—lung cancer	0.000484	0.00123	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Paclitaxel—lung cancer	0.000483	0.00123	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—lung cancer	0.000483	0.00099	CbGpPWpGaD
Cisatracurium Besylate—Hypersensitivity—Docetaxel—lung cancer	0.000479	0.00122	CcSEcCtD
Cisatracurium Besylate—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—lung cancer	0.000476	0.000975	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—lung cancer	0.000474	0.000972	CbGpPWpGaD
Cisatracurium Besylate—Anaphylactic shock—Methotrexate—lung cancer	0.000469	0.00119	CcSEcCtD
Cisatracurium Besylate—Pruritus—Docetaxel—lung cancer	0.00046	0.00117	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Methotrexate—lung cancer	0.00046	0.00117	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—lung cancer	0.000459	0.00094	CbGpPWpGaD
Cisatracurium Besylate—Skin disorder—Methotrexate—lung cancer	0.000455	0.00116	CcSEcCtD
Cisatracurium Besylate—Hypotension—Methotrexate—lung cancer	0.000438	0.00111	CcSEcCtD
Cisatracurium Besylate—Convulsion—Doxorubicin—lung cancer	0.000431	0.00109	CcSEcCtD
Cisatracurium Besylate—Hypertension—Doxorubicin—lung cancer	0.000429	0.00109	CcSEcCtD
Cisatracurium Besylate—CHRND—Transmission across Chemical Synapses—BRAF—lung cancer	0.000427	0.000875	CbGpPWpGaD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000421	0.00107	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Methotrexate—lung cancer	0.000418	0.00106	CcSEcCtD
Cisatracurium Besylate—Rash—Docetaxel—lung cancer	0.00041	0.00104	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Docetaxel—lung cancer	0.00041	0.00104	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Doxorubicin—lung cancer	0.000406	0.00103	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—lung cancer	0.000405	0.000829	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—lung cancer	0.000403	0.000827	CbGpPWpGaD
Cisatracurium Besylate—Nervous system disorder—Doxorubicin—lung cancer	0.000398	0.00101	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Doxorubicin—lung cancer	0.000396	0.00101	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Doxorubicin—lung cancer	0.000394	0.001	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—lung cancer	0.000384	0.000788	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—lung cancer	0.000383	0.000785	CbGpPWpGaD
Cisatracurium Besylate—Hypotension—Doxorubicin—lung cancer	0.000379	0.000963	CcSEcCtD
Cisatracurium Besylate—Urticaria—Methotrexate—lung cancer	0.000372	0.000945	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Transmission across Chemical Synapses—BRAF—lung cancer	0.000363	0.000744	CbGpPWpGaD
Cisatracurium Besylate—Dyspnoea—Doxorubicin—lung cancer	0.000362	0.000919	CcSEcCtD
Cisatracurium Besylate—CHRND—Transmission across Chemical Synapses—MDM2—lung cancer	0.000358	0.000733	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Transmission across Chemical Synapses—RAF1—lung cancer	0.000357	0.000731	CbGpPWpGaD
Cisatracurium Besylate—Hypersensitivity—Methotrexate—lung cancer	0.000345	0.000877	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Transmission across Chemical Synapses—BRAF—lung cancer	0.000345	0.000707	CbGpPWpGaD
Cisatracurium Besylate—Pruritus—Methotrexate—lung cancer	0.000332	0.000842	CcSEcCtD
Cisatracurium Besylate—CHRND—Neuronal System—BRAF—lung cancer	0.000327	0.000671	CbGpPWpGaD
Cisatracurium Besylate—Urticaria—Doxorubicin—lung cancer	0.000322	0.000818	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Transmission across Chemical Synapses—MDM2—lung cancer	0.000304	0.000624	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Transmission across Chemical Synapses—RAF1—lung cancer	0.000303	0.000621	CbGpPWpGaD
Cisatracurium Besylate—Hypersensitivity—Doxorubicin—lung cancer	0.000299	0.000759	CcSEcCtD
Cisatracurium Besylate—Rash—Methotrexate—lung cancer	0.000296	0.00075	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Methotrexate—lung cancer	0.000295	0.00075	CcSEcCtD
Cisatracurium Besylate—CHRNA2—Transmission across Chemical Synapses—MDM2—lung cancer	0.000289	0.000592	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Transmission across Chemical Synapses—RAF1—lung cancer	0.000288	0.00059	CbGpPWpGaD
Cisatracurium Besylate—Pruritus—Doxorubicin—lung cancer	0.000287	0.000729	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neuronal System—BRAF—lung cancer	0.000278	0.00057	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Neuronal System—MDM2—lung cancer	0.000274	0.000562	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Neuronal System—RAF1—lung cancer	0.000273	0.00056	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Neuronal System—BRAF—lung cancer	0.000264	0.000542	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—lung cancer	0.000261	0.000535	CbGpPWpGaD
Cisatracurium Besylate—Rash—Doxorubicin—lung cancer	0.000256	0.00065	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Doxorubicin—lung cancer	0.000256	0.000649	CcSEcCtD
Cisatracurium Besylate—CHRNA1—Neuronal System—MDM2—lung cancer	0.000233	0.000478	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Neuronal System—RAF1—lung cancer	0.000232	0.000476	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—lung cancer	0.000222	0.000455	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Neuronal System—MDM2—lung cancer	0.000221	0.000454	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Neuronal System—RAF1—lung cancer	0.000221	0.000452	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—lung cancer	0.000211	0.000432	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Transmission across Chemical Synapses—HRAS—lung cancer	0.000196	0.000402	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Transmission across Chemical Synapses—HRAS—lung cancer	0.000167	0.000342	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Transmission across Chemical Synapses—HRAS—lung cancer	0.000159	0.000325	CbGpPWpGaD
Cisatracurium Besylate—CHRND—Neuronal System—HRAS—lung cancer	0.00015	0.000308	CbGpPWpGaD
Cisatracurium Besylate—CHRNA1—Neuronal System—HRAS—lung cancer	0.000128	0.000262	CbGpPWpGaD
Cisatracurium Besylate—CHRNA2—Neuronal System—HRAS—lung cancer	0.000122	0.000249	CbGpPWpGaD
